An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models.
Chen X, Xue L, Ding X, Zhang J, Jiang L, Liu S, Hou H, Jiang B, Cheng L, Zhu Q, Zhang L, Zhou X, Ma J, Liu Q, Li Y, Ren Z, Jiang B, Song X, Song J, Jin W, Wei M, Shen Z, Liu X, Wang L, Li K, Zhang T.
Chen X, et al. Among authors: shen z.
Front Immunol. 2022 Feb 22;13:828319. doi: 10.3389/fimmu.2022.828319. eCollection 2022.
Front Immunol. 2022.
PMID: 35273608
Free PMC article.